domvanalimab – Talk Bio

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

1 week ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials

Gilead and Arcus Report Positive Results for TIGIT Approach in Gastric Cancer Trial

2 weeks ago talkbio0Tagged Arcus, domvanalimab, Gilead, Malignant neoplasm of stomach, TIGIT gene, zimberelimab

Gilead; Arcus; TIGIT; Gastric Cancer; Domvanalimab; Zimberelimab

Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development

12 months ago talkbio0Tagged Arcus, Cancer Therapeutic Procedure, Clinical Trials, Combo, domvanalimab, TIGIT gene, zimberelimab

Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials